Amyloid neuropathies

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 564-572

  Adams, David ^a,c   Lozeron, Pierre ^a,c   Lacroix, Catherine ^b,c  

^a Universite Paris Sud   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Department of Neurology   (France)

Author keywords

AL; diagnosis; familial amyloidosis with polyneuropathy; therapy; transthyretin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXYCYCLINE; GELSOLIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PREALBUMIN; SERUM AMYLOID P; SERUM AMYLOID P MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG;

AMYLOID NEUROPATHY; ANTISENSE THERAPY; CARDIOMYOPATHY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FAMILIAL AMYLOID POLYNEUROPATHY; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; LIVER GRAFT; MASS SPECTROMETRY; NERVE BIOPSY; NONHUMAN; REVIEW; SKIN BIOPSY; SURVIVAL; URINARY TRACT INFECTION;

AMYLOID NEUROPATHIES; AMYLOIDOSIS, FAMILIAL; ANIMALS; ENDEMIC DISEASES; HUMANS; LIVER TRANSPLANTATION; PREALBUMIN;

EID: 84866326173     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357bdf6     Document Type: Review

References (48)

1. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001; 248:647-657. (Pubitemid 32695860)
2. Coutinho P, DeSilva A, Lima J, Barbosa A. Amyloid and amyloidosis. In: Glenner GG CP, Freitas F, editors. Forty years of experience with type I amyloid neuropathy: review of 483 cases. Amsterdam, the Netherlands: Exerpta Medica; 1980. pp. 88-98.
3. Do Amaral B, Coelho T, Sousa A, Guimaraes A. Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 2009; 16:232-238.
4. Cappellari M, Cavallaro T, Ferrarini M, et al. Variable presentations of TTRrelated familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 2011; 16:119-129.
5. Adams D, Lozeron P, Theaudin M, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy (FAP) in France. Amyloid 2012; 19 (S1):61-64.
6. Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from nonendemic areas. J Neurol Neurosurg Psychiatry 2012; 83:152-158.
7. Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011; 18:53-62.
8. England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Neurology 2009; 72:185-192.
9. Mathis S, Magy L, Diallo L, et al. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2012; 45:26-31.
10. Tojo K, Tsuchiya-Suzuki A, Sekijima Y, et al. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Amyloid 2010; 17:32-35.
11. Shirota Y, Iwata A, Ishiura H, et al. A case of atypical amyloid polyneuropathy with predominant upper-limb involvement with the diagnosis unexpectedly found at lung operation. Intern Med 2010; 49:1627-1631.
12. Riboldi G, Del Bo R, Ranieri M, et al. Tyr78Phe transthyretin mutation with predominant motor neuropathy as the initial presentation. Case Rep Neurol 2011; 3:62-68.
13. Yang NC, Lee MJ, Chao CC, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology 2010; 75:532-538.
14. Adams D, Lozeron P, Theaudin M, et al. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid 2011; 18 (Suppl 1):93-95.
15. van Gameren I, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54:2015-2021. (Pubitemid 43877954)
16. Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68:195-199.
17. Luigetti M, Conte A, Del Grande A, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci 2012. [Epub ahead of print]
18. Suhr OB, Andersen O, Aronsson T, et al. Report of five rare or previously unknown amyloidogenic transthyretin mutations disclosed in Sweden. Amyloid 2009; 16:208-214.
19. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002; 58:1001-1007. (Pubitemid 34298536)
20. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012; 33:1120-1127.
21. Algalarrondo V, Dinanian S, Juin C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012; 9:1069-1075.
22. Wilczek HE, Larsson M, Ericzon BG. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011; 18 (Suppl 1):188-190.
23. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78:637-643.
24. Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011; 18:200-205.
25. Gustafsson S, Ihse E, Henein MY, et al. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012; 93:1017-1023.
26. Okamoto S, Hornsten R, Obayashi K, et al. Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 2011; 17:122-128.
27. Ohya Y, Okamoto S, Tasaki M, et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today 2011; 41:1211-1218.
28. Hara R, Kawaji T, Ando E, et al. Impact of liver transplantation on transthyretinrelated ocular amyloidosis in Japanese patients. Arch Ophthalmol 2010; 128:206-210.
29. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75:324-327.
30. Ihse E, Suhr OB, Hellman U, Westermark P. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 2011; 89:171-180.
31. Tsuchiya-Suzuki A, Yazaki M, Kametani F, et al. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met. Hum Pathol 2011; 42:236-243.
32. Barreiros AP, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010; 16:314-323.
33. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012; 421:185-203.
34. Coelho T, Maia L, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012. [Epub ahead of print]
35. Berk JL, Suhr OB, Sekijima Y, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid 2012; 19 (S1):37-38.
36. Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010; 8:74.
37. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (S1):34-36.
38. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33:609-618.
39. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19 (S1):43-44.
40. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468:93-97.
41. Adams D, Lacroix C, Antonini T, et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid 2011; 18 (Suppl 1):169-172.
42. Llado L, Baliellas C, Casasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16:1386-1392.
43. Conceicao I, Evangelista T, Castro J, et al. Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation. Muscle Nerve 2010; 42:836-839.
44. Tracy JA, Dyck PJ, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve 2010; 41:710-715.
45. Luigetti M, Papacci M, Bartoletti S, et al. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid 2012; 19:53-55.
46. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012; 26:137-154.
47. Katoh N, Matsuda M, Yoshida T, et al. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. Muscle Nerve 2010; 41:138-143.
48. Dingli D, Tan TS, Kumar SK, et al. Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. Neurology 2010; 74:913-918.